Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey-Reference-Cited by-同舟云学术

Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

Published:2020-05-22 Issue:12 Volume:55 Page:2335-2338
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Sellner Leopold^ORCID,Schetelig Johannes^ORCID,Koster Linda,Choi Goda,Blaise Didier^ORCID,Beelen Dietrich,Schianca Fabrizio Carnevale,Passweg Jakob,Schanz Urs,Gyan Emmanuel,Sora Federica,Kröger Nicolaus,Wulf Gerald. G.,Van Gorkom Gwendolyn,Mayer Jiri,Orvain Corentin,Bourhis Jean Henri,Jindra Pavel^ORCID,Potter Victoria,Zallio Francesco,Vandenberghe Elisabeth,Robinson Stephen,Hayden Patrick J.,Yakoub-Agha Ibrahim,Montoto Silvia,Dreger Peter,

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-020-0946-x.pdf

Reference15 articles.

1. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–18. https://doi.org/10.1056/NEJMoa1314583.

2. Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica. 2017;102:e156–e159. https://doi.org/10.3324/haematol.2016.151738.

3. Norman JE, Schouten HC, Dreger P, Robinson SP. The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies. Bone Marrow Transpl. 2018. https://doi.org/10.1038/s41409-018-0372-5.

4. Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018;124:1733–42.

5. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203. https://doi.org/10.1182/blood-2016-03-707133.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐life efficacy and safety of idelalisib in 55 double‐refractory follicular lymphoma patients;British Journal of Haematology;2022-08-24

2. Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study;Cancers;2022-01-27

3. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party;Bone Marrow Transplantation;2020-10-02